Surrozen Earns $10M Milestone Payment As Boehringer Advances Development Of SZN-413 For Retinal Vascular Diseases, Prepares For Clinical Testing
Portfolio Pulse from Benzinga Newsdesk
Surrozen has received a $10 million milestone payment from Boehringer Ingelheim as the latter advances the development of SZN-413 for retinal vascular diseases and prepares for clinical testing.
September 24, 2024 | 12:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Surrozen received a $10 million milestone payment from Boehringer Ingelheim, indicating progress in the development of SZN-413 for retinal vascular diseases.
The milestone payment signifies a successful advancement in the partnership with Boehringer Ingelheim, which is a positive indicator for Surrozen's future prospects and could boost investor confidence.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90